Generic Oncology Sterile Injectable Market By Product Type (Biosimilars, Non-Biosimilars), By End-User Industry (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), By Distribution Channel (Direct Sales, Third-Party Distributors, Online Sales), By Formulation Type (Vials, Pre-Filled Syringes, Ampoules), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Generic Oncology Sterile Injectable Market was valued at USD 16.2 billion in 2024-e and will surpass USD 40.3 billion by 2030; growing at a CAGR of 13.9% during 2025 - 2030.

The global generic injectable market continues to expand rapidly as the demand for cost-effective alternatives to branded injectables grows across various therapeutic areas. This market encompasses a broad range of product types, distribution channels, formulation types, and end-user industries. The adoption of generic injectables is spurred by rising healthcare costs and the increasing focus on improving access to affordable treatment options. As healthcare systems and patients seek affordable alternatives to expensive branded injectable drugs, the generic injectable market is expected to witness significant growth across several regions, driven by advancements in drug development and manufacturing technologies.

Biosimilars Segment is Largest Owing to Growing Adoption in Oncology

Within the generic injectable market, the biosimilars segment holds the largest share, largely driven by their role in the oncology space. Biosimilars are highly similar to existing branded biologic drugs, but they offer a more affordable alternative. As the patent exclusivities of several blockbuster biologics expire, the uptake of biosimilars has surged. Oncology, in particular, is the largest therapeutic area for biosimilars, as several monoclonal antibodies and other biologic therapies for cancer treatments have entered the biosimilar market. The lower cost of biosimilars compared to original biologics makes them an attractive option for healthcare systems, especially in regions with limited access to expensive treatments.

The regulatory approval processes for biosimilars have become more streamlined in recent years, further fueling their growth. Regulatory agencies such as the FDA and EMA have developed guidelines for approving biosimilars, boosting confidence in their safety and efficacy. This has led to wider acceptance and adoption of biosimilars by hospitals, clinics, and other healthcare providers, contributing to their prominence in the generic injectable market.

Online Sales Channel is Fastest Growing Owing to Digital Transformation in Healthcare

In terms of distribution channels, online sales is the fastest growing segment, driven by the increasing adoption of e-pharmacy services and digital healthcare platforms. The online sales channel offers the advantage of convenience, allowing consumers to order medications from the comfort of their homes. During the COVID-19 pandemic, the shift towards online healthcare services accelerated, with patients increasingly turning to online pharmacies for injectable medications, including generic injectables. This shift is expected to continue, supported by the growth of mobile health apps, e-prescribing, and telemedicine, which make it easier for patients to access injectable drugs online.

The rapid growth of online pharmacies is also being supported by the increasing availability of digital platforms that allow for more seamless transactions and patient engagement. Additionally, online sales have expanded beyond traditional medications to include injectables, making it easier for patients in remote areas to access essential drugs. As the online sales channel continues to grow, healthcare providers are adapting to meet patient needs in the digital space, ensuring a broader reach for generic injectables.

Vials Segment is Largest Owing to Longevity and Versatility in Applications

The vials formulation type is the largest in the generic injectable market, mainly due to its long shelf life and versatility in various therapeutic applications. Vials are widely used for the packaging of injectable medications, especially in the oncology and diabetes treatment segments, where injectables are commonly administered. Vials are easy to store, transport, and handle, making them a popular choice for both hospitals and clinics. Additionally, the use of vials in the generic injectable market has been enhanced by innovations in vial designs, which now offer increased safety features such as tamper-proof seals and enhanced sterility.

Vials are also favored by healthcare professionals because they allow for precise dosage control, which is critical when administering injectables. As the demand for oncology and diabetes injectables grows, the vials segment is expected to continue to dominate the market due to their practicality, safety, and cost-effectiveness.

Hospitals End-User Industry is Largest Owing to Increased Injectable Drug Utilization

The hospitals end-user industry remains the largest segment in the generic injectable market, primarily due to the high demand for injectables in inpatient settings. Hospitals administer a significant number of injectable drugs daily, ranging from cancer treatments to pain management and emergency care. The use of generic injectables in hospitals helps reduce the overall cost of treatment, especially in critical care units where injectable drugs are commonly used. As the prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases continues to rise, hospitals are increasingly turning to generic injectables as part of their treatment protocols to ensure that patients have access to affordable medications.

Furthermore, the increasing number of hospital admissions and the expansion of healthcare facilities in emerging markets further support the dominance of hospitals as the primary end-user segment in the generic injectable market. The availability of generic alternatives allows hospitals to optimize their budgets while ensuring the best possible care for patients.

North America Region is Largest Owing to High Healthcare Expenditure

North America is the largest region for the generic injectable market, accounting for a significant share of the global market. The region's dominance is driven by its advanced healthcare infrastructure, high healthcare expenditure, and the increasing adoption of generic injectables in hospitals, clinics, and other healthcare facilities. The U.S., in particular, represents a large portion of the market, as the country has a large volume of injectable drug utilization in therapeutic areas such as oncology, cardiovascular diseases, and neurological disorders.

The U.S. also has a robust regulatory framework that facilitates the approval and market entry of generic injectables, contributing to the high adoption rate. Additionally, healthcare reforms and cost-containment strategies have driven hospitals and other healthcare providers to embrace generic injectables as a more affordable alternative to branded injectable drugs, further boosting the market in North America.

Competitive Landscape and Leading Companies

The generic injectable market is highly competitive, with several global players dominating the landscape. Leading companies include Teva Pharmaceuticals, Sandoz (Novartis), Mylan Pharmaceuticals, Pfizer, and Cipla Limited. These companies are engaged in continuous product development, strategic partnerships, and acquisitions to strengthen their position in the market. Teva Pharmaceuticals, for example, has made significant strides in the oncology injectable segment, while Mylan and Sandoz have been at the forefront of the biosimilar injectable space.

The competitive landscape is also marked by a strong focus on regulatory compliance, as approval from agencies like the FDA and EMA is crucial for market success. Companies are focusing on expanding their portfolios of generic injectables, particularly in high-demand therapeutic areas such as oncology and diabetes. The market is expected to witness increased consolidation as larger companies acquire smaller biotech firms and startups to enhance their product offerings and strengthen their market presence

Recent Developments:

  • Teva has launched a new generic version of a high-demand oncology injectable, offering a cost-effective alternative to a branded chemotherapy drug.
  • Sandoz’s oncology biosimilars have received FDA approval, strengthening its position in the U.S. market with alternatives to blockbuster cancer treatments.
  • Pfizer has expanded its oncology injectable portfolio with the acquisition of a biosimilar product line, broadening its cancer treatment offerings.
  • Mylan has entered into a partnership with a global distributor to expand access to its oncology injectable drugs in emerging markets.
  • Amgen has launched a new generic oncology injectable in the Asia-Pacific region, responding to the rising demand for affordable cancer medications

List of Leading Companies:

  • Teva Pharmaceuticals
  • Sandoz (Novartis)
  • Mylan Pharmaceuticals
  • Pfizer Inc.
  • Cipla Limited
  • Amgen Inc.
  • Dr. Reddy’s Laboratories
  • Fresenius Kabi
  • Baxter International
  • Sun Pharmaceutical Industries Ltd.
  • Lupin Pharmaceuticals
  • Viatris (formerly Mylan)
  • Hikma Pharmaceuticals
  • Zydus Cadila
  • Accord Healthcare

Report Scope:

Report Features

Description

Market Size (2024-e)

USD 16.2 Billion

Forecasted Value (2030)

USD 40.3 Billion

CAGR (2025 – 2030)

13.9%

Base Year for Estimation

2024-e

Historic Year

2023

Forecast Period

2025 – 2030

Report Coverage

Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments

Segments Covered

Generic Oncology Sterile Injectable Market By Product Type (Biosimilars, Non-Biosimilars), By End-User Industry (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies), By Distribution Channel (Direct Sales, Third-Party Distributors, Online Sales), By Formulation Type (Vials, Pre-Filled Syringes, Ampoules)

Regional Analysis

North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa)

Major Companies

Teva Pharmaceuticals, Sandoz (Novartis), Mylan Pharmaceuticals, Pfizer Inc., Cipla Limited, Amgen Inc., Dr. Reddy’s Laboratories, Fresenius Kabi, Baxter International, Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Viatris (formerly Mylan), Hikma Pharmaceuticals, Zydus Cadila, Accord Healthcare

Customization Scope

Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements

1. Introduction

   1.1. Market Definition

   1.2. Scope of the Study

   1.3. Research Assumptions

   1.4. Study Limitations

2. Research Methodology

   2.1. Research Approach

      2.1.1. Top-Down Method

      2.1.2. Bottom-Up Method

      2.1.3. Factor Impact Analysis

  2.2. Insights & Data Collection Process

      2.2.1. Secondary Research

      2.2.2. Primary Research

   2.3. Data Mining Process

      2.3.1. Data Analysis

      2.3.2. Data Validation and Revalidation

      2.3.3. Data Triangulation

3. Executive Summary

   3.1. Major Markets & Segments

   3.2. Highest Growing Regions and Respective Countries

   3.3. Impact of Growth Drivers & Inhibitors

   3.4. Regulatory Overview by Country

4. Generic Oncology Sterile Injectable Market, by Product Type (Market Size & Forecast: USD Million, 2023 – 2030)

   4.1. Biosimilars

   4.2. Non-Biosimilars

5. Generic Oncology Sterile Injectable Market, by End-User Industry (Market Size & Forecast: USD Million, 2023 – 2030)

   5.1. Hospitals

   5.2. Clinics

   5.3. Retail Pharmacies

   5.4. Online Pharmacies

6. Generic Oncology Sterile Injectable Market, by Distribution Channel (Market Size & Forecast: USD Million, 2023 – 2030)

   6.1. Direct Sales

   6.2. Third-Party Distributors

   6.3. Online Sales

7. Generic Oncology Sterile Injectable Market, by Formulation Type (Market Size & Forecast: USD Million, 2023 – 2030)

   7.1. Vials

   7.2. Pre-Filled Syringes

   7.3. Ampoules

8. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030)

   8.1. Regional Overview

   8.2. North America

      8.2.1. Regional Trends & Growth Drivers

      8.2.2. Barriers & Challenges

      8.2.3. Opportunities

      8.2.4. Factor Impact Analysis

      8.2.5. Technology Trends

      8.2.6. North America Generic Oncology Sterile Injectable Market, by Product Type

      8.2.7. North America Generic Oncology Sterile Injectable Market, by End-User Industry

      8.2.8. North America Generic Oncology Sterile Injectable Market, by Distribution Channel

      8.2.9. North America Generic Oncology Sterile Injectable Market, by Formulation Type

      8.2.10. By Country

         8.2.10.1. US

               8.2.10.1.1. US Generic Oncology Sterile Injectable Market, by Product Type

               8.2.10.1.2. US Generic Oncology Sterile Injectable Market, by End-User Industry

               8.2.10.1.3. US Generic Oncology Sterile Injectable Market, by Distribution Channel

               8.2.10.1.4. US Generic Oncology Sterile Injectable Market, by Formulation Type

         8.2.10.2. Canada

         8.2.10.3. Mexico

    *Similar segmentation will be provided for each region and country

   8.3. Europe

   8.4. Asia-Pacific

   8.5. Latin America

   8.6. Middle East & Africa

9. Competitive Landscape

   9.1. Overview of the Key Players

   9.2. Competitive Ecosystem

      9.2.1. Level of Fragmentation

      9.2.2. Market Consolidation

      9.2.3. Product Innovation

   9.3. Company Share Analysis

   9.4. Company Benchmarking Matrix

      9.4.1. Strategic Overview

      9.4.2. Product Innovations

   9.5. Start-up Ecosystem

   9.6. Strategic Competitive Insights/ Customer Imperatives

   9.7. ESG Matrix/ Sustainability Matrix

   9.8. Manufacturing Network

      9.8.1. Locations

      9.8.2. Supply Chain and Logistics

      9.8.3. Product Flexibility/Customization

      9.8.4. Digital Transformation and Connectivity

      9.8.5. Environmental and Regulatory Compliance

   9.9. Technology Readiness Level Matrix

   9.10. Technology Maturity Curve

   9.11. Buying Criteria

10. Company Profiles

   10.1. Teva Pharmaceuticals

      10.1.1. Company Overview

      10.1.2. Company Financials

      10.1.3. Product/Service Portfolio

      10.1.4. Recent Developments

      10.1.5. IMR Analysis

    *Similar information will be provided for other companies 

   10.2. Sandoz (Novartis)

   10.3. Mylan Pharmaceuticals

   10.4. Pfizer Inc.

   10.5. Cipla Limited

   10.6. Amgen Inc.

   10.7. Dr. Reddy’s Laboratories

   10.8. Fresenius Kabi

   10.9. Baxter International

   10.10. Sun Pharmaceutical Industries Ltd.

   10.11. Lupin Pharmaceuticals

   10.12. Viatris (formerly Mylan)

   10.13. Hikma Pharmaceuticals

   10.14. Zydus Cadila

   10.15. Accord Healthcare

11. Appendix

A comprehensive market research approach was employed to gather and analyze data on the Generic Oncology Sterile Injectable Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Generic Oncology Sterile Injectable Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.

Research Approach -

Secondary Research

Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.

Primary Research

Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:

  • Validating findings and assumptions derived from secondary research
  • Gathering qualitative and quantitative data on market trends, drivers, and challenges
  • Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
  • Assessing the supply-side landscape, including technological advancements and recent developments

Market Size Assessment

A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Generic Oncology Sterile Injectable Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:

  1. Identification of key industry players and relevant revenues through extensive secondary research
  2. Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
  3. Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources

Bottom Up and Top Down -

Data Triangulation

To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.

NA

Please state your requirements.


I have read the Terms & Conditions and Privacy Policy. I agree to its terms.

Report Buying Options